Latest news with #Ambati
New Indian Express
a day ago
- Politics
- New Indian Express
YSRCP leader Ambati's graft charges motivated: TDP MLA Dhulipalla
GUNTUR: TDP MLA Dhulipalla Narendra has lashed out at YSRCP leader Ambati Rambabu, calling his corruption allegations against the government 'baseless and politically motivated.' Addressing the media here on Sunday, he said Ambati's remarks were scripted from Tadepalli rather than grounded in the realities of Ponnur. 'Ambati neither knows the people of Ponnur nor its fields. Reading notes written by clerks at Tadepalli Palace does not make him aware of farmers' problems,' Dhulipalla said. The TDP MLA asserted that the coalition government repaired canals in its first days in office to ensure irrigation and drinking water. 'If there was corruption in canal works, was Ambati sleeping for a year? Only after losing power did the YSRCP suddenly remember farmers and crops,' he remarked. He pointed out that 16,718 acres of crop losses from last year's floods were compensated with Rs 16.31 crore to 9,132 farmers. Rejecting corruption allegations, he said the bridge works in question occurred under the previous government. The present government had issued repeated notices to the contractor to expedite work, and he challenged Ambati to an open debate on the issue. The TDP MLA also highlighted welfare measures such as 'Annadata Sukhibhava and PM-Kisan', which together provided Rs 13.96 crore directly to 21,567 farmers in his constituency. He accused the YSRCP of looting cooperative banks, farmer insurance, and RBK funds..
New Indian Express
23-06-2025
- Politics
- New Indian Express
Case booked against YSRCP leader Ambati in incidents related to Jagan's visit to Sattenapalli
GUNTUR: Police have registered cases against senior YSRCP leaders, including former minister Ambati Rambabu, in connection with recent incidents surrounding former CM YS Jagan Mohan Reddy's visit to Sattenapalli, and party State coordinator Sajjala Ramakrishna Reddy for allegedly making derogatory comments against Amaravati women protesters. Ambati is facing charges for violating prohibitory orders, and obstructing police from discharging their duties during Jagan's visit to Rentapalla on June 18. According to police, Ambati, along with his brother Murali, allegedly broke through barricades at Korrapadu, engaged in heated exchanges with police, and even manhandled personnel on duty. Cases have been registered against him at Nallapadu, Old Guntur, and Sattenapalli Rural police stations under IPC Sections 188, 332, 353 and 427. In a separate case, Sajjala has been booked under Bharatiya Nyaya Sanhita Sections 79, 352, 353(2), and 196(1) at Tadepalli police station. The FIR was registered based on a complaint by Kambhampati Sirisha, leader of Amaravati Dalit JAC, who alleged that Sajjala made caste-based derogatory remarks against women protesters. According to sources, Sajjala has approached the AP High Court seeking anticipatory bail. Meanwhile, former CBI Joint Director and advocate VV Lakshminarayana has filed an impleading petition on behalf of the complainant, opposing grant of bail to Sajjala.
Time of India
22-06-2025
- Politics
- Time of India
YSRCP slams govt for politicizing tragic accident
Vijayawada: The YSRCP has strongly condemned the TDP coalition's attempt to politicize the tragic accident that resulted in the death of party activist Cheeli Singaiah during YS Jagan Mohan Reddy 's recent visit. Former minister Ambati Rambabu said that it was unfortunate to portray the accident as a big conspiracy, instead of treating the matter with the sensitivity it deserves. "The ruling coalition is attempting to exploit it for political gain," Ambati alleged. The YSRCP leader pointed out that Prathipadu YSRCP in-charge Kiran Kumar immediately rushed to the hospital upon receiving news of the accident and remained with the bereaved family until the postmortem was completed, offering them full support. The following day, senior party leaders from the district, including Ambati, visited the family and handed over a cheque of Rs 10 lakh as financial assistance. The district superintendent of police, Satish Kumar, has clearly stated that the vehicle involved in the accident was a private vehicle, not part of YS Jagan Mohan Reddy's convoy. The driver and owner were identified and interrogated, confirming that the accident had no connection with the convoy itself. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Brass Krishna Idols For Prosperity & Protection In Life Luxeartisanship Shop Now Undo Despite this, the ruling coalition released a video four days after the incident, falsely blaming YS Jagan Mohan Reddy. Ambati criticized the Naidu-led govt for failing to provide adequate security to YS Jagan Mohan Reddy, a Z+ security protectee. "A rope party and road clearance team must lead the convoy, but the government has deliberately compromised on Jagan's security," Ambati alleged. This is not an isolated instance, as similar security failures were observed during YS Jagan Mohan Reddy's tours in Rapthadu and Podili. The coalition govt is using these lapses to orchestrate a character assassination campaign against the former CM, he claimed. The YSRCP demands a transparent and impartial investigation into both the accident and the security lapses that continue to put the life of a Z+ protectee at risk. "We urge the state govt to immediately rectify these lapses and stop using such incidents to settle political scores," Ambati said. The party reiterates that human tragedy must never be used as a political weapon.
Hans India
28-05-2025
- Health
- Hans India
Low-cost HIV drug to improve vision in patients with common diabetes complication
New Delhi: An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more effectively, according to preliminary results of a clinical trial. The drug, lamivudine, could represent an important new option for millions of patients with diabetic macular edema (DME) -- a condition affecting about one in 14 people with diabetes. It causes fluid to build up in the retina of the eye and affects vision. As the drug is taken orally it potentially offers patients an alternative to monthly injections directly into their eyes, said the researchers from the University of Virginia in the US. "The mechanism of action of lamivudine is also different from that of existing treatments, so we could also develop combination therapies," said researcher Jayakrishna Ambati, from UVA Health's Center for Advanced Vision Science. The researchers explained that lamivudine is effective against DME because it blocks the activity of inflammasomes -- important agents of our immune systems. Inflammasomes normally act as sensors of infections, but they have also been implicated in the development of DME. For the study, published in the journal Med, the researchers enrolled two dozen adults with DME in a small randomised clinical trial. Participants were randomly assigned to receive either lamivudine or a harmless placebo, in addition to injections of the drug bevacizumab into their eyes starting after four weeks. Participants who received lamivudine showed significant vision improvements even before their first eye injections. Their ability to read letters on an eye chart improved by 9.8 letters (about 2 lines on the eye chart) at four weeks, while the participants receiving a placebo saw their ability decrease by 1.8 letters. A month after the bevacizumab injections, the lamivudine recipients had improved by a whopping 16.9 letters (more than 3 lines on the eye chart), while the placebo group, receiving bevacizumab alone, had increased by only 5.3. The results suggest that lamivudine may work both alone and in conjunction with bevacizumab injections, though larger studies will be needed to bear that out, the researchers said. Lamivudine alone could be life-changing for patients in many areas of the world with limited access to specialty doctors or who are unable to afford or travel to monthly eye appointments, Ambati said, while calling for more trials of lamivudine with larger numbers of patients.
Yahoo
15-05-2025
- Health
- Yahoo
Alzheimer's disease could be prevented by antiviral drug already on market
An existing drug for HIV could double as a preventative therapy for Alzheimer's disease, according to researchers. NRTIs (nucleoside reverse transcriptase inhibitors) are antivirals that are approved to treat HIV infection, but scientists from UVA Health at the University of Virginia found that patients taking them were less likely to develop the common form of dementia. There was a roughly 10% annual reduction in the risk of developing Alzheimer's disease in people taking NRTIs for every year of use of these drugs, according to lead study author Dr. Jayakrishna Ambati, M.D., professor of ophthalmology at UVA, who spoke to Fox News Digital about the finding. Alzheimer's Brain Treatment Shows Promising Results In New Study After coming across another mechanism that could potentially prevent Alzheimer's, the researchers analyzed 24 years of health insurance data, including 270,000 patients. The Alzheimer's risk reduction among patients taking NRTIs was "significant and substantial," the researchers wrote in the findings, which were published in the journal Alzheimer's & Dementia. Read On The Fox News App Now, the UVA team is calling for clinical trials of NRTIs to gauge their use for treating Alzheimer's. Approximately 10 million people worldwide are diagnosed with the common dementia each year. Alzheimer's Rates Have Reached Staggering Number As Experts Call For Change "This level of protection could translate into 60,000 fewer cases of Alzheimer's disease every year in our country, and up to one million fewer cases every year around the world," Ambati told Fox News Digital. In addition to keeping the HIV virus from replicating, NRTIs also prevent the activation of inflammasomes, proteins that are involved in the development of Alzheimer's. "We had previously shown that NRTIs blocked the inflammasome, so it wasn't altogether surprising that people taking NRTIs might be protecting against this disease," Ambati noted. "However, the degree of protection against Alzheimer's was quite surprising." Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News senior medical analyst, was not involved in the study but commented on the findings. "Inflammasomes are intracellular protein complexes that trigger the release of inflammatory cytokines," he told Fox News Digital. "HIV uses these inflammasomes to fight the immune system." "These chemicals are likely responsible for making Alzheimer's worse, or for accelerating the process of cognitive decline based on neuro-inflammation." Rebecca Edelmeyer, Ph.D., vice president of Scientific Engagement at the Alzheimer's Association in Chicago, also reviewed the study's findings, which she called "interesting." 'I'm A Neurologist — Here's Why Dementia Is Rising And How To Reduce Your Risk' "Further research and specifically designed clinical trials are needed to fully understand the potential future use of NRTIs to reduce the risk of Alzheimer's, but the study highlights the potential role drug repurposing can play in advancing new Alzheimer's treatments," she told Fox News Digital. Repurposing existing drugs can offer a "promising pathway," according to Edelmayer. As existing drugs' safety and side effects are often already known, the studies can be quicker and less expensive than with new treatments, she added. The research team acknowledged some limitations of the study. "Like all retrospective health insurance database studies, the findings of our study are an association between this class of drugs and the development of Alzheimer's disease," Ambati told Fox News Digital. "They don't necessarily provide a cause and effect — however, the fact that we found this link in multiple databases increases confidence in this result." Siegel agreed that the new study is observational, but noted that it takes place over many years. "It also shows that only this particular HIV drug — inflammasome — dramatically decreases the risk of Alzheimer's, not the other HIV drugs, including protease inhibitors," the doctor said. "I think this is convincing preliminary evidence that warrants further study," Siegel added. "It is very possible that this drug may be useful in Alzheimer's prevention, given the increasing evidence implicating immune dysregulation and inflammation as causes of AD." Looking ahead, the researchers have developed a new drug called K9. Like NRTIs, the novel medication blocks inflammasomes, but is "safer and more effective," according to Ambati. Click Here To Sign Up For Our Health Newsletter "The fact that the new drug reversed memory loss and improved spatial learning in mice further increases confidence in our findings," he told Fox News Digital. The UVA team now plans to test K9 in clinical trials for Azheimer's. Ambati noted that people should not take NRTIs for Alzheimer's prevention unless they are in the context of a clinical trial. "If interested, they should be on the lookout for such trials for themselves or loved ones who may be affected," he advised. For more Health articles, visit Nearly seven million people in the U.S. are currently living with Alzheimer's, and the number is expected to reach 13 million by 2050, according to the Alzheimer's Association. The UVA study was funded in part by the UVA Strategic Investment Fund and the National Institutes of article source: Alzheimer's disease could be prevented by antiviral drug already on market
